Companies operating in the enteral and parenteral medical nutrition market constantly focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the enteral and parenteral medical nutrition market are mentioned such as- In June 2022, Nestle Health Science acquired The Better Health Company (TBHC) from CDH Investments and TBHC founding shareholders. The acquisition includes the GO Healthy brand, along with its vitamin and supplement lineups; the Manuka honey brand Egmont; and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins, minerals, and supplements. The acquisition helped Nestle Health Science strengthen and expand its presence in New Zealand, Australia, and other Asia Pacific countries. In September 2021, Abbott introduced plant-based protein and organic food ingredients—PediaSure Harvest and Ensure Harvest—for people relying on feeding tubes. Harvest products can be used as sole-source nutrition or a supplement to satisfy daily nutrition requirements. In December 2020, Abbott launched the Pedialyte Hydration Solution, a new formulation designed with key nutrients to support immune health. Pedialyte with immune support includes prebiotics, vitamin B12, vitamin C, vitamin E, and zinc, specifically chosen for their importance in the development and improvement of the immune system. In October 2020, Nutricia (part of Danone) acquired Real Food Blends. The company helps contribute to the real food blends mission and portfolio by bringing more unique and nutritious choices to children and adults dependent on feeding tubes. Therefore, introducing products such as ready-to-drink and ready-to-use nutritional supplements; the development of innovative products targeting various health issues; and strategic moves such as expansions and acquisitions allow companies in the enteral and parenteral medical nutrition market to create new or improved products and new business to remain competitive in the market. Thus, such strategic growth initiatives create significant growth opportunities in the market.
Asia Pacific (APAC) is the fastest-growing regional market for enteral and parenteral medical nutrition and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Factors contributing to the growth of the market in the region are the rising prevalence of chronic diseases and the growing presence of market players across the region, conferring the highest manufacturing of enteral & parenteral nutrition products. Furthermore, supportive government initiatives and research in the field of nutrition boost market growth.
Strategic insights for the Asia Pacific Enteral and Parenteral Medical Nutrition provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Asia Pacific Enteral and Parenteral Medical Nutrition refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.Asia Pacific Enteral and Parenteral Medical Nutrition Strategic Insights
Asia Pacific Enteral and Parenteral Medical Nutrition Report Scope
Report Attribute
Details
Market size in 2023
US$ 2,339.32 Million
Market Size by 2028
US$ 3,352.69 Million
Global CAGR (2023 - 2028)
7.5%
Historical Data
2021-2022
Forecast period
2024-2028
Segments Covered
By Indication
By Nutrition Type
By Form
By Product Type
By Route of Administration
Regions and Countries Covered
Asia-Pacific
Market leaders and key company profiles
Asia Pacific Enteral and Parenteral Medical Nutrition Regional Insights
Asia Pacific Enteral and Parenteral Medical Nutrition Market Segmentation
The Asia Pacific enteral and parenteral medical nutrition market is segmented into indication, nutrition type, form, product type, route of administration, age group, and distribution channel, and country.
Based on indication, the Asia Pacific enteral and parenteral medical nutrition market is segmented into elderly, gastrointestinal disorders, diabetes, cancer, respiratory disorders, alzheimer’s disease, dementia, renal disease, liver failure, post covid-19, and other indications. The elderly segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023. Gastrointestinal disorders are segmented into IBD, IBS, and others.
Based on nutrition type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held a larger share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on form, the Asia Pacific enteral and parenteral medical nutrition market is segmented into liquid, powder, and semi solid. The liquid segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on product type, the Asia Pacific enteral and parenteral medical nutrition market is segmented into general and disease specific. The general segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on route of administration, the Asia Pacific enteral and parenteral medical nutrition market is segmented into oral, tube feed, and parenteral. The parenteral segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on age group, the Asia Pacific enteral and parenteral medical nutrition market is segmented into above 60 years, 18-60 years, 3-18 years, and below 3 years. The above 60 years segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Based on distribution channel, the Asia Pacific enteral and parenteral medical nutrition market is segmented into a hospital pharmacies, retail stores, e-commerce, and others. The hospital pharmacies segment held the largest share of the Asia Pacific enteral and parenteral medical nutrition market in 2023
Based on country, the Asia Pacific enteral and parenteral medical nutrition market is segmented into China, Japan, India, Australia, South Korea, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. China dominated the share of the Asia Pacific enteral and parenteral medical nutrition market in 2023.
Abbott Laboratories; B. Braun SE; Baxter International Inc; Fresenius Kabi AG; Nestle SA; and Nutricia International BV are the leading companies operating in the Asia Pacific enteral and parenteral medical nutrition market.
The Asia Pacific Enteral and Parenteral Medical Nutrition Market is valued at US$ 2,339.32 Million in 2023, it is projected to reach US$ 3,352.69 Million by 2028.
As per our report Asia Pacific Enteral and Parenteral Medical Nutrition Market, the market size is valued at US$ 2,339.32 Million in 2023, projecting it to reach US$ 3,352.69 Million by 2028. This translates to a CAGR of approximately 7.5% during the forecast period.
The Asia Pacific Enteral and Parenteral Medical Nutrition Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Enteral and Parenteral Medical Nutrition Market report:
The Asia Pacific Enteral and Parenteral Medical Nutrition Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Enteral and Parenteral Medical Nutrition Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Enteral and Parenteral Medical Nutrition Market value chain can benefit from the information contained in a comprehensive market report.